Home / Pharmaceutical company intelligence
Bristol Mayer Biotech Pakistan logo
Pharmaceutical company intelligence

Bristol Mayer Biotech Pakistan

Private pharmaceutical and nutraceutical manufacturer · Lahore · Pakistan

Lahore-based pharmaceutical, biotechnology and nutraceutical manufacturer with domestic manufacturing and healthcare-product operations.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗
ShareSend this page
Regulatory & corporate identity

Company profile

Public-source profile
Legal / official name
Bristol Mayer Biotech Pakistan (Pvt.) Ltd.
Company type
Private pharmaceutical and nutraceutical manufacturer
Address
73-B, Guldasht Town, Zarrar Shaheed Road, Lahore 54000, Pakistan · 54000
Phone
+92 321 5171711
Profile details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DSL 05-352-0068-109282D 3 linked products · source seen 12 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Location recorded

A Google Maps embed has not yet been configured for this recorded location.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx3product presentations
G3generic molecules
DF1dosage-form groups
TA1therapeutic areas
PKR3current price records
REG3registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage67%
products with at least one like-for-like comparator
Therapeutic classification67%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixBristol Mayer Biotech PakistanShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bristol-mayer-biotech-pakistanGenerated 19 Aug 2026Reproductive & genitourinary2 · 67%Unclassified1 · 33%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioBristol Mayer Biotech PakistanDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bristol-mayer-biotech-pakistanGenerated 19 Aug 20263presentationsTablet3 · 100%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionBristol Mayer Biotech PakistanCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bristol-mayer-biotech-pakistanGenerated 19 Aug 20262comparable productsBelow peer median2 · 100%Near peer median0 · 0%Above peer median0 · 0%Company median price position-50.9%Lowest-price equivalents2Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsBristol Mayer Biotech PakistanCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bristol-mayer-biotech-pakistanGenerated 19 Aug 2026Zafa Pharmaceutical Laboratories (P…2 shared67% overlapAspin Pharma2 shared67% overlapNabiqasim Industries (Pvt) Ltd.,1 shared33% overlapM/s. Genix Pharma (Pvt) Ltd.1 shared33% overlapAtco Laboratories Limited1 shared33% overlapMacter International Limited1 shared33% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Formulation footprint

Dosage forms

Tablet3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2100% of comparable products
Near market median0within ±5% of median
Above market median00% of comparable products
Lowest-price equivalents2ties included
Company median price position -50.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Regulatory & price activity

Observed database signals

Registration numbers3
Price-history records3
Products with price history0
Source records with multiple versions0
Latest MedInfoBase verification12 Aug 2026
Latest effective price date12 Aug 2026
Latest source observation12 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

3 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit pricePrice position
Accecabo Cabergoline 0.5 mg Tablet 10's 135861 PKR 3,120.00 PKR 312.00/tablet No comparator
Aevora Levonorgestrel 1.5 mg Tablet 1's 135859 PKR 15.00 PKR 15.00/tablet 50% below median
Misovance Misoprostol 200 mcg Tablet 28's 135858 PKR 280.00 PKR 10.00/tablet 52% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.